CN100518744C - A bacterium-resisting nursing article - Google Patents

A bacterium-resisting nursing article Download PDF

Info

Publication number
CN100518744C
CN100518744C CNB2007101208863A CN200710120886A CN100518744C CN 100518744 C CN100518744 C CN 100518744C CN B2007101208863 A CNB2007101208863 A CN B2007101208863A CN 200710120886 A CN200710120886 A CN 200710120886A CN 100518744 C CN100518744 C CN 100518744C
Authority
CN
China
Prior art keywords
chitosan
acid
water
compositions
carboxymethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CNB2007101208863A
Other languages
Chinese (zh)
Other versions
CN101156868A (en
Inventor
潘学理
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Qingdao Tong Doctor Marine Biotechnology Co., Ltd.
Original Assignee
BEIJING HAILI'AN BIOTECHNOLOGY Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BEIJING HAILI'AN BIOTECHNOLOGY Co Ltd filed Critical BEIJING HAILI'AN BIOTECHNOLOGY Co Ltd
Priority to CNB2007101208863A priority Critical patent/CN100518744C/en
Publication of CN101156868A publication Critical patent/CN101156868A/en
Application granted granted Critical
Publication of CN100518744C publication Critical patent/CN100518744C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention discloses a bacteriostatic composition containing carboxymethyl chitosan, water-soluble chitosan and chitosan oligosaccharide, and the usage of the composition in articles with bacteriostatic activity.

Description

A kind of bacterium-resisting nursing article
Invention field
The present invention relates to a kind of bacteria inhibiting composition, form the material of this bacteria inhibiting composition, and the application of this bacteria inhibiting composition.Especially described bacteria inhibiting composition contains carboxymethyl chitosan, water-soluble chitosan and oligochitosan.
Background of invention
Vaginitis, cervicitis, pelvic inflammatory disease is women's a common disease, simultaneously, women's pudendum and vagina are because the cause specific on the physiological structure, female private part and vagina very easily infect staphylococcus aureus, Candida albicans and mycete, Pseudomonas aeruginosa and bacillus pyocyaneus, escherichia coli, yeast, infusorian etc., so vaginitis, cervicitis, pelvic inflammatory disease etc. are the FAQs of women's pudendum and vagina, prior art has other drugs such as adopting antibiotic and other dosage forms to the associated treatment of these problems, but the use antibiotic can be to liver, kidney and relevant organ have certain toxic and side effects, also can influence the normal profitable strain of vagina, thereby cause the destruction of and defence capability self-cleaning, also easily cause vagina vagina, urethra, the cross infection of anus.
At present, though the medicine of the antibacterial and gynecological's pudendum diseases such as treatment vaginitis, cervix uteri inflammation of vagina also occurred much being used for, but its dosage form is all very traditional, produce effects and effect are direct inadequately, the most drug effect is single, and external used medicine is many based on washing liquid, and curative effect is not very desirable, and still belong to new shape dosage form at present as the intravaginal medication gel of gynecological inflammation, still have many problems not solve.
Chitosan (chitosan) has another name called poly-glucosamine or chitosan, is the macromolecule straight chain type polysaccharide of chitin deacetylate.Chitin is a kind of natural polymer, is only second to cellulose in the output of occurring in nature, is the organic compounds containing nitrogen of quantity maximum on the earth.The formal name used at school of chitin is β (1,4)-2-acetylaminohydroxyphenylarsonic acid 2-deoxy-D-glucose, by the N-acetylglucosamine with β-1,4 glycosidic bond condensations form, extensively be present in the cell wall of the cell wall of carapace, fungus (yeast, mycete) of carapace, the insecticide of shrimp, Eriocheir sinensis and algae, its structural formula is seen Fig. 1.
Chitin stands degraded and deacetylation process at nature, the chitosan of the chitin of generation different molecular weight and different molecular weight, different deacetylations, and its structural formula is seen Fig. 2.Because deacetylated reaction has destroyed the regularity of chitin molecule structure, therefore, the chitosan solubility property is greatly improved than chitin, and chemical property is also comparatively active.Owing to have free amine group and activity hydroxy in the chitosan molecule, substituted radical can enter O-position and N-position during reaction simultaneously, and therefore, corresponding product has the O-carboxymethyl chitosan, N-carboxymethyl chitosan and N, O-carboxymethyl chitosan (Muzzarelli, 1988).
The major physiological function of chitosan comprises blood fat reducing and cholesterol reducing; Antimicrobial acivity; The human body immunity improving ability; Antitumor; Blood fat reducing; Blood pressure lowering etc.
For antimicrobial acivity, existing bibliographical information comprises that Wang Guanghua etc. (1992) finds that chitosan has stronger inhibitory action to toadstool in the common food such as staphylococcus aureus, escherichia coli and Salmonella typhimurium.Wherein the 0-carboxymethyl chitosan has good inhibitory effect to staphylococcus aureus, and is then relatively poor to colibacillary bacteriostasis.Along with the increase of concentration, the antibacterial activity of 0-carboxymethyl chitosan obviously strengthens, and when concentration is 0.5%, the suppression ratio of staphylococcus aureus is reached 100%; When concentration is 1%, almost can suppress the growth of antibacterial fully, and and the relation between the molecular weight is very close, along with the reduction of molecular weight, fungistatic effect significantly improves, when molecular weight greater than 10000 the time, do not possess bacteria resistance function, and when molecular weight less than 5000 the time, bacteriostatic activity obviously strengthens (Chen Lingyun etc., 2000).No etc. (2002) discover that chitosan has stronger antibacterial action to gram positive bacteria, and its minimum inhibitory concentration is from 0.05% to more than 0.1%, and also relevant with molecular weight.The antibacterial activity of chitosan is also multi-form relevant with it.Kim etc. (2003) have compared the fungistatic effect of tegument polysaccharide, lipase degrade chitosan and 0-carboxymethyl (O-CM) chitosan, the fungistatic effect of finding the tegument polysaccharide is better than the lipase degrade chitosan, and the fungistatic effect that derives from the 0-CM chitosan of lipase degraded is better than deriving from natural O-CM chitosan.
The bacteriostasis of carboxymethyl chitosan has following two kinds of mechanism: the one, and chitosan forms one deck polymeric membrane by being adsorbed on cell surface, stop nutrient substance to intracellular transportation, or the absorption chitosan is at surface of cell membrane, changed the selection permeability of cell membrane, cause Cytoplasm to run off, cell plasmolysis, thus play the bacteriostasis and sterilization effect.The 2nd, positively charged chitosan penetrating enters in the cyton, has the Cytoplasm of electric charge in the adherent cell body, and flocculation takes place, upset the normal physiological activity of cell, or the transcribing of DNA in the blocking-up bacterial body, thereby suppress the breeding (Chen Lingyun etc., 2000) of antibacterial.
Consider that chitosan is a kind of natural product, nontoxic, non-stimulated to human body, have bacteriostasis simultaneously, but the present invention is made as bacterium-resisting nursing article with its processing.Chitosan is directly used in antibacterial, still has the too high problem of minimal inhibitory concentration (MIC), has the problem of preparation difficulty simultaneously.The present invention adopts the compositions that contains carboxymethyl chitosan, water-soluble chitosan and oligochitosan to address the above problem.
Description of drawings:
Accompanying drawing 1 is the structural formula of chitin;
Accompanying drawing 2 is structural formulas of chitosan.
Goal of the invention
The objective of the invention is to: provide a kind of and do not add hormone and antibiotics, have no side effect, determined curative effect, can be used for external bacteria inhibiting composition antibacterial and the treatment gynecological inflammation.
The present invention is achieved by the following technical solutions.
Calculate by weight percentage, compositions contains water-soluble chitosan and accounts for 10%--40%, and carboxymethyl chitosan is not less than 50%, and oligochitosan accounts for 1%--20%.The compositions finally percentage by weight in aqueous solution is 0.5%--5%.
1) takes by weighing carboxymethyl chitosan and be added in the purified water, stirred 5 hours, to all dissolvings;
2) take by weighing water-soluble chitosan and oligochitosan and join in the purified water, stirred 5 hours, to all dissolvings;
3) the 2 step solution that will prepare slowly add in the 1 step solution, stir simultaneously, avoid producing floccule; 300 mesh sieves filter, and check clarity; Packing.
Optimized technical scheme is:
Calculate by weight percentage, compositions contains water-soluble chitosan and accounts for 20%--30%, and carboxymethyl chitosan accounts for 60%--70%, and oligochitosan accounts for 5%--15%.The compositions finally percentage by weight in aqueous solution is 2%--4%.
Most preferred technical scheme is:
Calculate by weight percentage, compositions contains water-soluble chitosan and accounts for 25%, and carboxymethyl chitosan accounts for 65%, and oligochitosan accounts for 10%.The compositions finally percentage by weight in aqueous solution is 3%.
As used herein, term herein has following implication:
After " water-soluble chitosan " is meant that chitosan is through physics and/or chemical treatment, the chitosan with good water-solubility.
The preparation of water-soluble chitosan at present mainly contains 3 kinds of methods: 1. under gentle homogeneous phase condition, the deacetylation of control chitosan prepares water-soluble chitosan about 50%; 2. utilize the light base in chitin, the chitosan molecule structure and the reactivity of amido, on its molecular backbone, introduce hydrophilic group, obtain water soluble derivative group; 3. degrade chitosan obtains the water-soluble products of low molecular mass, can be divided into acid degradation method, oxidation degradation method and enzymatic degradation method 3 big class groups.Oxidation degradation method is many a kind of methods of studying at present, mainly contains H 2O 2Method, H 2O 2-HCl method, H 2O 2-NaCl method, ClO 2Method etc.
Water-soluble chitosan can pass through prior art for preparing, or buys from market.For example can utilize Chinese patent application CN1225923, CN1283634, CN1283635, CN1554267, CN1563106, CN1803849; And Xue Hanghua etc., the preparation of water-soluble low-molecular chitosan, the tropical crops journal, 2005 04 phases, condition are big etc., the preparation research of water-soluble chitosan, feed industry, document disclosed methods such as phase preparation in 2005 14.
In the present invention, preferably pass through with chitosan after the acetum of 1%--2% is handled 24 hours preparation water solublity gram polysaccharide.
Term " carboxymethyl chitosan " is meant the water-soluble products that chitosan obtains through carboxy methylation.Owing to have free amine group in the chitosan molecule, substituted radical can enter 0 and N during reaction, and then corresponding product has 0-carboxymethyl chitosan, N-carboxymethyl chitosan to ward off and N, 0-carboxymethyl chitosan.If chitin directly carries out shuttle and methylates, then product is a carboxymethyl chitin.
The carboxymethylation reaction of chitosan on hydroxyl is similar to the preparation of carboxymethyl cellulose.Chitosan alkalizes at low temperatures with strong caustic, carries out carboxymethylation reaction with monoxone, obtains the 0-CM chitosan.If at room temperature carry out quaternization, then product is ()-CM chitosan.If be heated to 60 ℃, can obtain N, the O-CM chitosan.The generation of various products, Temperature Influence are important.Because chitosan is insoluble to alkaline solution, and this reaction is in the heterogeneous system.Another kind of reaction is to carry out in acid medium, adopts glyoxalic acid as the shuttle methylating reagent, and reaction is only occurred on the N, can obtain the N-CM chitosan after reduction.Utilize this reaction that the 0-CM chitosan also can be obtained N again with behind the glyoxalic acid condensating reductive, the O-CM chitosan, the characteristics of this reaction are to be substituted with selectivity, do not need heating, can carry out in aqueous solution. and be homogeneous system.
Carboxymethyl chitosan can pass through prior art for preparing, or buys from market.For example can utilize Chinese patent application CN 1080640, CN 1329095, CN02110793, CN 1431229, CN 1594367, and Chen Xin etc., N, the research of O-carboxymethyl chitosan preparation condition and mutation performance, food research and development, 2000 05 phases, Yang Jisheng etc., the applied research of carboxymethyl chitosan (CMCH) in cosmetics, fine chemistry industry, 1997 04 phases.
Term " oligochitosan " claims oligomerization glucosamine, chitin oligosaccharide again, and the product degradation of chitosan deacetylated by chitin (chitin) obtains, and is the oligosaccharide that is formed by connecting by β-1,4 glycosidic bond by 2-10 glucosamine.It also is a large amount of natural alkaline aminopolysaccharides that exist of occurring in nature, and good water solubility is easily absorbed by animal body.
The main preparation methods of chitosan is chemical method, physics method and bioanalysis at present.Chemical method mainly contains: acid-hydrolysis method, oxidizing process, supercritical fluid method, coordination edman degradation Edman etc.Physics method such as microwave method, supercritical ultrasonics technology, light degradation method, gamma ray method etc.Bioanalysis mainly contains enzymic degradation, reactor and enzymatic degradation, degrades glycosyl transfer method etc. in addition in human body.
Oligochitosan can pass through prior art for preparing, or buys from market.For example can utilize Chinese patent application CN 1302809, CN 1396185, CN 1401652, CN 1772915, CN 1654483, CN 1746193, CN1803849, CN 1680569, CN1884308, CN 1944466, CN1935887; And Chen Haiyan etc., the preparation of oligochitosan and physiological function thereof, Chinese feedstuff, 2007 04 phases, Ji Ying etc., the preparation of oligochitosan and component analysis, contemporary Chinese is used pharmacy, 2003 years 03 phases.
Can also contain other antibacterial medicines in the compositions of the present invention, for example medicine, plant extract etc., comprise, but be not limited to, for example penicillin, streptomycin, clotrimazole, ceftriaxone, sulfadiazine, furan azoles quinoline, norfloxacin, ketoconazole, azithromycin, gentamycin, Roxithromycin, ciprofloxacin, lincomycin, vancomycin etc.The preferred present composition contains clotrimazole.
Institute's referenced patents document and non-patent literature all are hereby incorporated by with its full content herein.
As for the solvent that can be used in the bacteria inhibiting composition of the present invention, can use not any solvent that can have a negative impact to this active component, water for example, alcohol (methanol for example, ethanol, ethylene glycol, propylene glycol, glycerol or the like), ketone (for example, acetone, methyl ethyl ketone or the like), ether (oxolane for example, diethylene glycol dimethyl ether or the like), aliphatic hydrocarbon (for example, hexane, kerosene or the like), aromatic hydrocarbon (for example, benzene, toluene, dimethylbenzene, methyl naphthalene or the like), halogenated hydrocarbon (for example, aminoform, carbon tetrachloride or the like), acid acylamide (for example, dimethyl formamide or the like), ester (for example, methyl acetate, ethyl acetate, butyl acetate, fatty glyceride or the like), and nitrol (for example, acetonitrile or the like).These solvents be can use separately or use two or multiple solvent united.
As for the dispersant that can be used in the bacteria inhibiting composition of the present invention, can use any dispersion chaste tree that can not have a negative impact to this active component, for example, a kind of surfactant.As for such surfactant, can use soap class, higher alcohol sulfate, alkyl sulfonic acid, alkyl allyl sulphonic acid, quaternary ammonium salt, alkoxyamine, fatty acid ester, polyether compound, anhydro sorbitol chemical compound or the like.These dispersants can use separately or can two or multiplely unite use.
As for the carrier that can be used in the anti-mattress compositions of the present invention, can use any dispersion chaste tree that this active component is not had adverse effect, for example the clay class (for example, Kaolin, Bentonite, acid clay or the like), the Pulvis Talci class (for example, Pulvis Talci, agalmatolite powder or the like), Silicon stone class (for example, kieselguhr, silica anhydride, mica powder or the like), Alumina, sulfur powder, active carbon or the like. these carriers can use separately or can two or multiplely unite use.
The present invention is compositions arbitrarily, all can with pharmaceutically acceptable acid or alkali reaction, form corresponding salt.Preferred and the salifiable example of inorganic base shape comprises and alkali metal that the salt as sodium, potassium etc. form with alkaline-earth metal, as the salt that calcium, magnesium etc. form, reaches the salt that forms with aluminum, ammonium.Preferably the example of the salt that forms with organic base comprises trimethylamine, triethylamine, pyridine, ethanolamine, diethanolamine, triethanolamine, hexanamine, N, formed salt such as N-dibenzyl vinyl diamidogen.Preferred and the salifiable example of inorganic salt shape comprises and formed salt such as hydrochloric acid, hydrobromic acid, nitric acid, sulphuric acid, phosphoric acid.Preferably with the salifiable example of organic acid institute shape comprise and formed salt such as formic acid, acetic acid, trichloroacetic acid, fumaric acid, oxalic acid, tartaric acid, maleic acid, citric acid, succinic acid, malic acid, methanesulfonic acid, benzenesulfonic acid, P-toluene sulfonic acide.
The term " drug acceptable carrier " that the present invention uses refers to that this active component of promotion that uses is processed into the excipient or the adjuvant of preparation in pharmacy.Said preparation can be by oral, intramuscular, intraperitoneal, subcutaneous or intravenous administration.Preferably, described preparation, particularly those include percentage by weight and are about 0.01-99.99% active component and excipient and/or adjuvant such as tablet, dragee, suppository and capsular preparation and suitable solution.
The excipient that is fit to that the present invention uses comprises the filler such as polysaccharide, for example lactose or sucrose, mannitol or sorbitol, cellulose derivative, magnesium sulfate, such as the calcium phosphate of tricalcium phosphate or calcium hydrogen phosphate, and such as the bonding agent of gelatinized corn starch, for example corn starch, wheaten starch, rice fecula, potato starch, gelatin, tragacanth and/or polyvinylpyrrolidone.
The adjuvant that is fit to that the present invention uses comprises fluid regulation agent and lubricant, for example Talcum, Silicon stone, stearic acid or its salt (such as magnesium stearate) and/or Polyethylene Glycol.Provide suitable bag quilt to the sugar-coat core, if necessary, it can tolerate gastric juice.For this purpose, spissated polysaccharide solution can be adopted, arabic gum, Talcum, polyvinylpyrrolidone, Polyethylene Glycol and/or titanium dioxide, lacquer solution and suitable organic solvent or solvent mixture arbitrarily can be contained.In order to produce the bag quilt of tolerance gastric juice, i.e. enteric coating adopts and such as the suitable cellulose preparation of acetylcellulose phthalic acid ester or hydroxypropylmethyl cellulose phthalate.Can in tablet or sugar-coat bag quilt, add dyestuff or pigment.
Compositions among the present invention can be formulated into the injection system such as intravenous, subcutaneous and intramuscular injection, the form of suppository or sublingual tablet.Generally accepted method is come the pharmaceutical preparation of preparation example such as injection, suppository, sublingual tablet, tablet and capsular dosage form in employing this area.
, if desired, pH regulator agent, buffer agent, solubilizing agent, suspending agent, stabilizing agent and antiseptic can be mixed in the described active ingredient during injection in preparation, carry out the preparation of intravenous, subcutaneous or intramuscular injection agent subsequently according to conventional methods.
The example of solubilizing agent comprises polyoxyethylene hydrogenated castor oil, polysorbate80, nicotiamide, polyethylene glycol oxide anhydro sorbitol first quarter moon cinnamic acid ester, Polyethylene Glycol and Castor Oil Fatty Acid ethyl ester.The example of suspending agent comprises methylcellulose, polysorbate80, hydroxyethyl-cellulose, arabic gum, powdered tragacanth, sodium carboxymethyl cellulose and polyethylene glycol oxide Arlacel-20.
The example of stabilizing agent comprises sodium sulfite, sodium pyrosulfite and ester, examples of preservatives bag p-oxybenzene acid methyl ester, p-oxybenzene acetoacetic ester, sorbic acid, phenol, cresol and chlorocresol.
In the present invention, when reactive compound or composition oral administration, can adopt the form of tablet or capsule or aqueous solution or suspension.When adopting tablet, normally used carrier comprises lactose, mannitol and corn starch, and adds the lubricant such as magnesium stearate usually.If the employing capsule form, reactive compound in hard gelatin capsule with exsiccant form administration, or at the gel or the liquid carrier that are fit to, liquid macrogol or intersect in the glue form administration in Perle for example.When the oral waterborne suspension of needs, active component can be mixed with emulsifying agent and suspending agent.If necessary, can also add some sweeting agent and/or flavoring agent.
Preferred compositions of the present invention occurs with the form of moisture film agent.The percentage by weight of compositions more preferably of the present invention in preparation is 2%-4%.
The liquid that compositions more preferably of the present invention is made is formed test kit with the sterilization non-woven fabrics made from water-soluble chitosan.During use, liquid preparation is poured on the sterilization non-woven fabrics, then, places and use the place.
Consider that the present composition has bacteriostatic activity, it can make and/or be used for having pharmaceutical preparation, medical apparatus and instruments, the skincare product of bacteriostatic activity.
Describe the present invention below in conjunction with embodiment, these embodiment myopia further specify the application's, but these embodiment do not play any qualification effect to protection scope of the present invention.
Describe when of the present invention when the reference specific embodiments, it is evident that those skilled in the art without departing from the spirit and scope of the present invention down, will carry out multiple variation and modification to these embodiments.
Embodiment
1. the compositions that only contains carboxymethyl chitosan, water-soluble chitosan and oligochitosan.
Take by weighing 1.95 kilograms of carboxymethyl chitosans and add 65 kilograms of purified water, stirred 5 hours, to all dissolvings; Take by weighing 0.75 kg of water soluble chitosan and 35 kilograms of purified water of 0.3 kilogram of oligochitosan adding, stirred 5 hours, to all dissolvings; The 2nd step solution is slowly added in the 1st step solution, stir simultaneously, avoid producing floccule; 300 mesh sieves filter, and check clarity; Packing.
2. the compositions that contains carboxymethyl chitosan, water-soluble chitosan, oligochitosan and clotrimazole
Take by weighing 1.95 kilograms of carboxymethyl chitosans and 65 kilograms of purified water of 5 kilograms of clotrimazoles addings, stirred 5 hours, to all dissolvings; Other step is the same.
3. the fungistatic effect of embodiment 1 compositions test.
Use candida albicans (ATCC10231) as test strain.0。The 03mol/l phosphate buffer is as negative control.Carry out according to GB15979-2002 " disposable use hygienic article sanitary standard " appendix C.
Fungistatic effect to staphylococcus aureus
Figure C200710120886D00131
Annotate: average clump count of matched group and scope 4.80 * 10 4(2.00 * 10 4-7.75 * 10 4) cfu/ml;
The negative control asepsis growth.
To colibacillary fungistatic effect
Figure C200710120886D00132
Annotate: average clump count of matched group and scope 6.75 * 10 4(5.50 * 10 4-7.55 * 10 4) cfu/ml;
The negative control asepsis growth.
Fungistatic effect to candida albicans
Figure C200710120886D00133
Figure C200710120886D00141
Annotate: average clump count of matched group and scope 2.16 * 10 4(1.44 * 10 4-3.20 * 10 4) cfu/ml;
The negative control asepsis growth.
Conclusion: compositions of the present invention and staphylococcus aureus, escherichia coli and candida albicans act on 10min respectively, and its average bacteriostasis rate is 100%, and said composition has stronger bacteriostasis.
4. effect contrast test
Be divided into four groups: a only contains the lotion of carboxymethyl chitosan among the embodiment 1, the lotion that b only contains water-soluble chitosan among the embodiment 1, the lotion that c only contains oligochitosan among the embodiment 1, the lotion of d embodiment 1, and the lotion of e embodiment 2, f be the lotion of the clotrimazole among the embodiment 2 only
Above five kinds of compositionss are offered the gynecology colpitis patient respectively use, effective percentage is respectively 50%, 40%, 53%, 70%, 85%, 72%.
This proves that compositions of the present invention has synergism.

Claims (3)

1, a kind of aqueous solution of bacteria inhibiting composition, wherein calculate by weight percentage, compositions is composed as follows: water-soluble chitosan accounts for 20%-30%, and carboxymethyl chitosan accounts for 60%-70%, oligochitosan accounts for 5%-15%, and the compositions finally percentage by weight in aqueous solution is 2%-4%.
2, aqueous solution as claimed in claim 1 is wherein calculated by weight percentage, and compositions is composed as follows: water-soluble chitosan accounts for 25%, and carboxymethyl chitosan accounts for 65%, and oligochitosan accounts for 10%, and the compositions finally percentage by weight in aqueous solution is 3%.
3, as the purposes of aqueous solution any as described in claim 1 and 2 in the colpitic medicine of preparation treatment.
CNB2007101208863A 2007-08-29 2007-08-29 A bacterium-resisting nursing article Active CN100518744C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CNB2007101208863A CN100518744C (en) 2007-08-29 2007-08-29 A bacterium-resisting nursing article

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CNB2007101208863A CN100518744C (en) 2007-08-29 2007-08-29 A bacterium-resisting nursing article

Publications (2)

Publication Number Publication Date
CN101156868A CN101156868A (en) 2008-04-09
CN100518744C true CN100518744C (en) 2009-07-29

Family

ID=39305189

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB2007101208863A Active CN100518744C (en) 2007-08-29 2007-08-29 A bacterium-resisting nursing article

Country Status (1)

Country Link
CN (1) CN100518744C (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102302797B (en) * 2011-09-15 2013-11-20 德州海利安生物科技股份有限公司 Medical colloid dressing and application thereof
CN102995402A (en) * 2012-11-17 2013-03-27 江志清 Method for solidifying pharmaceutical-grade chitosan oligosaccharide on fabric
CN103768089A (en) * 2013-05-13 2014-05-07 湖南华艳生物科技开发有限公司 Chitosan antibacterial lotion for gynecology and preparation method thereof
CN103446176B (en) * 2013-09-22 2015-08-26 福州乾正药业有限公司 Comprise pharmaceutical composition and the application thereof of chlorhexidine and oligochitosan
CN103784372B (en) * 2014-02-19 2016-05-11 北京德喜天地科贸有限公司 A kind of cosmetics that contain shitosan
CN107137759A (en) * 2015-12-23 2017-09-08 许盈 A kind of gel bandage and preparation method thereof
CN108403520A (en) * 2018-05-07 2018-08-17 青岛高新区尚达医药研究所 A kind of chitosan Mrs Chinese herbal medicine conditioning liquid and its application
CN108969794A (en) * 2018-10-08 2018-12-11 四川吉百瑞生物医疗科技有限公司 A kind of wound repair and oral care liquid dressing and preparation method thereof
CN110184815A (en) * 2019-04-25 2019-08-30 扬州纪元纺织有限公司 A kind of moisturizing antibacterial chitosan filament non-woven fabrics and preparation method thereof
CN113730283A (en) * 2021-10-14 2021-12-03 扬州日兴生物科技股份有限公司 Natural moisturizing and bacteriostatic facial mask containing compound functional chitosan

Also Published As

Publication number Publication date
CN101156868A (en) 2008-04-09

Similar Documents

Publication Publication Date Title
CN100518744C (en) A bacterium-resisting nursing article
Wang et al. Chitosan: Structural modification, biological activity and application
KR101155884B1 (en) Chemically modified polyaminosaccharide by a hydrocarbyl sultone compound
EP2775838B1 (en) Aqueous antimicrobial composition containing coniferous resin acids
Çakmak et al. Antibacterial activity of triclosan chitosan coated graft on hernia graft infection model
AU2017251217A1 (en) Anti-infective compositions comprising phytoglycogen nanoparticles
AU2015410635B2 (en) Synergistic composition for maintenance of healthy balance of microflora
KR101838404B1 (en) Composition for preventing or treating Acne containing oligo-chitosan as an effective component
CN102405935B (en) Protamine compounded preparation, preparation method and application thereof
CN110358098A (en) A kind of PEG bridging mannose-modified chitosan derivatives and preparation method thereof
Semwal et al. Chitosan: a promising substrate for pharmaceuticals
CN102030809B (en) Theasapogenol derivative with antibacterial effect as well as preparation method and application thereof
EP1357917B1 (en) Use of carbohydrates for eliminating intestinal infections in animals
Kumar et al. Dietary fibers and their derivatives for drug delivery applications: Advances and prospective
CN102614294A (en) Compound amoxicillin suspension injection and preparation method thereof
CN101301280A (en) Sustained release tablet products used as helminthic of livestock
CN101081860B (en) Polyene antibiotic diester compound
Rajkumari et al. Advances in biomedical application of chitosan and its functionalized nano-derivatives
Barakat et al. Nanosilver-marine fungal chitosan as antibiotic synergizers against sepsis fish bacteria
CN104095768A (en) Naringin contained weak acid antibacterial bath foam and preparation method thereof
US20240148778A1 (en) Glycoside inhibitors of yeast
JP7231163B2 (en) sugar and/or lipid metabolism improver
Mohyuddin ADVANCEMENT IN CHARACTERIZATION AND BIOLOGICAL ACTIVITIES OF CHITOSAN AND CHITOSAN OLIGOSACCHARIDES
JP5646164B2 (en) Branched chitosan derivative
CN107496441B (en) Use of cyclodextrins for the treatment and/or prevention of sepsis

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
ASS Succession or assignment of patent right

Owner name: DEZHOU HLA BIOLOGICAL TECHNOLOGY CO., LTD.

Free format text: FORMER OWNER: BEIJING HAILI'AN BIOTECHNOLOGY CO., LTD.

Effective date: 20110309

C41 Transfer of patent application or patent right or utility model
COR Change of bibliographic data

Free format text: CORRECT: ADDRESS; FROM: 102200 NO. 32, FUKANG ROAD, SCIENCE AND TECHNOLOGY PARK, CHANGPING DISTRICT, BEIJING TO: 253000 SOUTH SIDE OF DONGFANGHONG ROAD (NORTH OF FAST COMPANY), DEZHOU ECONOMIC DEVELOPMENT ZONE, SHANDONG PROVINCE

TR01 Transfer of patent right

Effective date of registration: 20110309

Address after: Red East Road on the south side of Dezhou Economic Development Zone in Shandong province 253000 (North Belfast company)

Patentee after: Dezhou Haili'an Biotechnology Co., Ltd.

Address before: 102200 No. 32 Fukang Road, Changping District science and Technology Park, Beijing

Patentee before: Beijing Haili'an Biotechnology Co., Ltd.

TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20171229

Address after: 272100 Shandong city of Jining Province, North West Guhuai electromechanical (Humanities Jiayuan Commercial Street)

Patentee after: Shandong humanities Co., Ltd.

Address before: Red East Road on the south side of Dezhou Economic Development Zone in Shandong province 253000 (North Belfast company)

Patentee before: Dezhou Haili'an Biotechnology Co., Ltd.

TR01 Transfer of patent right

Effective date of registration: 20190801

Address after: 266000 Qianjiashan Road 359, Huangdao District, Qingdao City, Shandong Province

Patentee after: Qingdao Tong Doctor Marine Biotechnology Co., Ltd.

Address before: 272100 Guhuai Road West, Mechatronics Road North, Jining City, Shandong Province (Humanities Jiayuan Street Commerce)

Patentee before: Shandong humanities Co., Ltd.

TR01 Transfer of patent right